GlassScriptPhysician profile
Sarah Edwards
NPI 1649695867
$1,811.83
in general payments reported to CMS, 2019-2025
14 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $187 · 2023: $392 · 2024: $949 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $806.33 | 2022-2025 | |
| Novo Nordisk INC | $182.39 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $142.34 | 2022-2025 | Airsupra |
| Exact Sciences Corporation | $135.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $128.03 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $92.49 | 2023-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $81.87 | 2022-2023 | |
| Shield Therapeutics INC | $79.90 | 2023-2025 | Accrufer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.46 | 2024-2025 | Caplyta |
| Vertex Pharmaceuticals Incorporated | $26.67 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $24.98 | 2023 | Seglentis |
| Neurocrine Biosciences, INC. | $16.07 | 2024 | Ingrezza |
| Phathom Pharmaceuticals, INC. | $13.60 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.